In this subgroup analysis of the HOT/NJLCG2001 trial, pembrolizumab monotherapy was the preferred treatment for elderly patients with advanced-stage non-small cell lung cancer with high PD-L1 expression. Here, CD274 is linked to non-small cell lung carcinoma.